In short
- Net sales were ¥518 million, down from ¥677 million in the prior fiscal year.
- The operating loss was ¥1,119 million, widening by ¥345 million from the prior fiscal year.
- The company generated 5 new Hits in fiscal 2026 and is targeting 3 Leads and 4 new Hits in fiscal 2027.
What they reported
this period against the same period a year earlier, and where they now expect the year to endSales
| Period | ¥m |
|---|---|
| FY24/9 Q4 | 90.0 |
| FY25/9 Q1 | 125.0 |
| FY25/9 Q2 | 93.0 |
| FY25/9 Q3 | 91.0 |
| FY25/9 Q4 | 368.0 |
| FY26/9 Q1 | 132.0 |
| FY26/9 Q2 | 121.0 |
| FY26/9 Q3 | 116.0 |
Net sales declined by ¥159 million from the prior fiscal year.
Operating profit
| Period | ¥bn |
|---|---|
| FY24/9 Q4 | -0.2 |
| FY25/9 Q1 | -0.2 |
| FY25/9 Q2 | -0.2 |
| FY25/9 Q3 | -0.3 |
| FY25/9 Q4 | -0.0 |
| FY26/9 Q1 | -0.3 |
| FY26/9 Q2 | -0.3 |
| FY26/9 Q3 | -0.2 |
The operating loss widened by ¥345 million from the prior fiscal year.
Ordinary profit
| Period | ¥bn |
|---|---|
| FY24/9 Q4 | -0.3 |
| FY25/9 Q1 | -0.2 |
| FY25/9 Q2 | -0.3 |
| FY25/9 Q3 | -0.3 |
| FY25/9 Q4 | -0.0 |
| FY26/9 Q1 | -0.3 |
| FY26/9 Q2 | -0.3 |
| FY26/9 Q3 | -0.2 |
The ordinary loss widened by ¥340 million from the prior fiscal year.
Net profit
| Period | ¥bn |
|---|---|
| FY24/9 Q4 | -0.5 |
| FY25/9 Q1 | -0.2 |
| FY25/9 Q2 | -0.3 |
| FY25/9 Q3 | -0.3 |
| FY25/9 Q4 | -0.0 |
| FY26/9 Q1 | -0.3 |
| FY26/9 Q2 | -0.3 |
| FY26/9 Q3 | -0.2 |
The net loss widened by ¥350 million from the prior fiscal year.
Their own numbers
figures this company chose to report, a year ago against nowThe company initiated 12 Hit discovery programs, including those started in the second half of fiscal 2025.
As of the end of September 2026, evaluation results had been obtained for 7 programs.
Hits were obtained in 5 of the 7 programs for which evaluation results were obtained.
The Hit acquisition rate among programs for which evaluation results were obtained was approximately 71%.
The company will invest in priority Leads in fiscal 2027 and is targeting the generation of 3 Leads.
The company is targeting the generation of 4 new Hits in fiscal 2027.
The objective response rate was 36.7% among 30 enrolled patients with advanced endometrial cancer.
The objective response rate was 57.1% among patients who had not received prior lenvatinib treatment.
The low–high ranges are Komori's estimate, not figures the company gave.
Everything else in the deck
New initiatives
- Select drug discovery targets with high market potential and accelerate Lead generation through concentrated investment in priority programs.
- Pursue business development activities with pharmaceutical companies in parallel with Lead generation and seek early licensing opportunities.
- The website was completely revamped in August 2026.
What decks usually leave out
COMPUTED = worked out by Komori from reported numbers; the rest are stated in this deckMargins and overheads
Overheads (selling and admin costs): ¥1.3bn
Financial targets
| Period | % |
|---|---|
| FY24/9 | 77.3 |
| FY25/9 | 87.6 |
Yearly figures are computed by Komori from J-Quants results data (ROE = net profit ÷ average equity). The last point is this year's forecast or latest figure. Targets show only when this deck states them.